- Home
- JLS vs SCLXW Comparison
JLS vs SCLXW Comparison
Compare JLS & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- SCLXW
- Stock Information
- Founded
- JLS 2009
- SCLXW N/A
- Country
- JLS United States
- SCLXW United States
- Employees
- JLS N/A
- SCLXW 111
- Industry
- JLS Investment Managers
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- SCLXW Health Care
- Exchange
- JLS Nasdaq
- SCLXW Nasdaq
- Market Cap
- JLS 97.1M
- SCLXW N/A
- IPO Year
- JLS N/A
- SCLXW N/A
- Fundamental
- Price
- JLS $18.93
- SCLXW $0.09
- Analyst Decision
- JLS
- SCLXW
- Analyst Count
- JLS 0
- SCLXW 0
- Target Price
- JLS N/A
- SCLXW N/A
- AVG Volume (30 Days)
- JLS 26.6K
- SCLXW 4.0K
- Earning Date
- JLS 01-01-0001
- SCLXW 03-07-2025
- Dividend Yield
- JLS 9.33%
- SCLXW N/A
- EPS Growth
- JLS N/A
- SCLXW N/A
- EPS
- JLS N/A
- SCLXW N/A
- Revenue
- JLS N/A
- SCLXW $55,152,000.00
- Revenue This Year
- JLS N/A
- SCLXW N/A
- Revenue Next Year
- JLS N/A
- SCLXW N/A
- P/E Ratio
- JLS N/A
- SCLXW N/A
- Revenue Growth
- JLS N/A
- SCLXW 22.02
- 52 Week Low
- JLS $15.48
- SCLXW $0.18
- 52 Week High
- JLS $17.97
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- JLS 73.80
- SCLXW N/A
- Support Level
- JLS $18.39
- SCLXW N/A
- Resistance Level
- JLS $18.89
- SCLXW N/A
- Average True Range (ATR)
- JLS 0.17
- SCLXW 0.00
- MACD
- JLS 0.04
- SCLXW 0.00
- Stochastic Oscillator
- JLS 98.65
- SCLXW 0.00
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.